Fig. 1: Overview of this MR study. | Nature Communications

Fig. 1: Overview of this MR study.

From: Systematic Mendelian randomization using the human plasma proteome to discover potential therapeutic targets for stroke

Fig. 1

Four O-link panels were used to measure plasma proteins in a subset of ~5000 samples from the INTERVAL study. Genetic variants associated with plasma protein levels were identified based on results from their corresponding GWAS. These genetic variants were then used as proxies for the protein level to test their relationship with stroke using data from the MEGASTROKE consortium for stroke outcomes (Primary MR), and with conventional stroke risk factors that were causally associated with stroke (Secondary MR). Colocalization analyses were performed to test the shared genetic associations of protein level, stroke outcomes and risk factors. Mediation analyses by two-step MR were performed for proteins that were potentially causally associated with both risk factors and stroke outcomes. We also tested the relationships of the potentially causal stroke proteins with 784 phenotypes in the UK Biobank to test a broad spectrum of potential effects of hypothetical therapeutic agents for stroke. #Stroke outcomes: any stroke; any ischaemic stroke; large artery stroke; cardioembolic stroke; small vessel stroke.

Back to article page